褪黑素补充对糖尿病合并慢性肾脏病患者代谢指标、氧化应激和炎症生物标志物影响的研究方案:双盲随机对照试验
该研究为双盲随机安慰剂对照试验,计划纳入48例糖尿病合并慢性肾脏病患者,随机接受5 mg褪黑素片或相同安慰剂每日两次、共10周,主要结局为氧化应激和炎症生物标志物变化,次要结局包括血脂、肾功能、血糖、血压、睡眠质量及体成分等指标。作者假设褪黑素可能通过调节氧化应激、炎症、脂代谢和胰岛素敏感性改善糖尿病合并慢性肾脏病状态。
要点
- 48例糖尿病合并慢性肾脏病患者随机接受5 mg褪黑素或安慰剂每日两次、共10周。
- 主要结局为氧化应激和炎症生物标志物变化,次要结局涵盖血脂、肾功能、血糖、血压及睡眠质量等。
- 作者假设褪黑素可能通过调节氧化应激、炎症、脂代谢和胰岛素敏感性改善糖尿病合并慢性肾脏病状态。
核心结论
- 作者假设褪黑素给药可能通过调节氧化应激、炎症、调节脂代谢和增加胰岛素敏感性等不同机制,对治疗糖尿病合并慢性肾脏病有用。
研究设计与样本
- 本研究为双盲、随机、安慰剂对照临床试验,计划纳入48例符合条件的糖尿病合并慢性肾脏病受试者,随机分配接受5 mg褪黑素片或相同安慰剂每日两次、共10周。
- 参与者被要求保持其平常饮食和体力活动。
- 研究使用实验室检查诊断糖尿病合并慢性肾脏病。
主要发现
- 主要结局为氧化应激和炎症生物标志物的变化。
- 次要结局包括血脂谱、肾功能指标、空腹血糖和血清胰岛素、收缩压和舒张压、血清磷浓度、睡眠质量、体重、体重指数和腰围的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chronic kidney disease (CKD) is a pervasive disease of the current century that usually affects the adult population, especially people with diabetes and hypertension. According to the recent studies, inflammation, oxidative stress, apoptosis, and mitochondrial dysfunction are determining risk factors in the pathogenesis of CKD. Melatonin as a strong antioxidant is produced in various tissues including the kidneys. The present clinical trial aims to examine the efficacy of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with CKD. METHODS: This is a double-blind, randomized, placebo-controlled clinical study that will be investigated the impacts of melatonin supplementation in diabetic patients with CKD. Laboratory findings will be applied to diagnose diabetic CKD. Forty-eight eligible diabetic subjects with CKD will be selected and randomly assigned to receive 5 mg melatonin tablets or identical placebo twice daily for 10 weeks. Participants will be asked to remain on their usual diet and physical activity. The primary outcome of this study is changes in oxidative stress and inflammatory biomarkers. The secondary outcomes include changes in lipid profile, renal function indicators, fasting blood sugar and serum insulin, systolic and diastolic blood pressure (SBP and DBP), serum phosphorous concentration, sleep quality, body weight, body mass index (BMI), and waist circumference (WC). Statistical analysis will be conducted using the SPSS software (version 25). DISCUSSION: We hypothesize that melatonin administration may be useful for treating diabetic CKD by modulating oxidative stress, inflammation, regulating lipid metabolism, and increasing insulin sensitivity through different mechanisms. The current trial will exhibit the effects of melatonin, whether negative or positive, on diabetic CKD status. ETHICAL ASPECTS: The current trial received approval from Medical Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran (IR.TUMS.SHARIATI.REC.1402.072). TRIAL REGISTRATION: This study had been registered in Iranian Registry of Clinical Trials. REGISTRATION NUMBER: IRCT20170202032367N9 on 11 August 2023. https://www.irct.ir/trial/70709 .
引用
- Sadeghi S, Hakemi MS, Pourrezagholie F, et al. Effects of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: study protocol for a double-blind, randomized controlled trial. Trials. 2024. PMID: 39533376. doi:10.1186/s13063-024-08584-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。